MVRIX has entered into a technology transfer agreement with Eyegene for MBT-002, a next-generation recombinant botulinum toxin candidate.

MBT-002 is a proprietary toxin featuring rapid onset, prolonged efficacy, and a favorable safety profile, offering strong potential and competitiveness in the evolving botulinum toxin market.

Building on this milestone, MVRIX is expanding its focus beyond aesthetic indications to develop therapeutic botulinum formulations, further accelerating its market growth.